Preclinical and clinical studies showed promising results in sarcoma, with the most robust PARPi efficacy evidence obtained in Ewing sarcomas bearing EWS–FLI1 or EWS–ERG genomic fusions [81]. This evidence concerns the gene EWSR1 and Ewing sarcoma.